Unraveling the Genetics of Human Obesity

David M. Mutch, Karine Clément*

ABSTRACT

The use of modern molecular biology tools in deciphering the perturbed biochemistry and physiology underlying the obese state has proven invaluable. Identifying the hypothalamic leptin/melanocortin pathway as critical in many cases of monogenic obesity has permitted targeted, hypothesis-driven experiments to be performed, and has implicated new candidates as causative for previously uncharacterized clinical cases of obesity. Meanwhile, the effects of mutations in the melanocortin-4 receptor gene, for which the obese phenotype varies in the degree of severity among individuals, are now thought to be influenced by one’s environmental surroundings. Molecular approaches have revealed that syndromes (Prader-Willi and Bardet-Biedl) previously assumed to be controlled by a single gene are, conversely, regulated by multiple elements. Finally, the application of comprehensive profiling technologies coupled with creative statistical analyses has revealed that interactions between genetic and environmental factors are responsible for the common obesity currently challenging many Westernized societies. As such, an improved understanding of the different “types” of obesity not only permits the development of potential therapies, but also proposes novel and often unexpected directions in deciphering the dysfunctional state of obesity.

Introduction

According to the World Health Organization (http://www.who.int), there are an estimated 1 billion adults who are overweight (body mass index > 25 kg/m^2), and 300 million of these are considered clinically obese (body mass index > 30 kg/m^2). Such staggering statistics clearly suggest that, despite the overt recognition of the taxing effects of obesity on both medical and social programs, Westernized societies are still succumbing to this global epidemic. While technological progress made over the last 20 years has yielded the tools necessary to comprehensively explore the perturbed biochemistry underlying the obese state, it has also demonstrated that interactions between genetic makeup and environment (G×E) are critical for the regulation of adipose mass function. As such, medical and nutritional recommendations based on genetically undefined and/or environmentally heterogeneous population-based studies have, not unsurprisingly, had minimal success in treating common diseases. It is precisely this lack of success that is paving the way for the widely discussed concepts of personalized medicine [1,2] and nutrition [3–5]. However, prior to our society realizing either of these ambitious concepts, the genetic components underlying common diseases such as obesity must be elucidated with confidence.

Over the past ten years, the study of genetically complex diseases has benefited greatly from the extraordinary advances made in molecular biology. While obesity was first thought to be a disease that obeys the rules of Mendelian inheritance, new technologies paint a far more complicated picture of this metabolic disease and have led to unsuspected and fascinating new developments. Obesity stemming from a single, naturally occurring dysfunctional gene (i.e., monogenic obesity) is both severe and rare when compared to the more common form of obesity, in which numerous genes make minor contributions in determining phenotype (i.e., polygenic obesities). Although some genetic candidates underlying monogenic obesities in the mouse have been defined, transferring this knowledge to humans has led to more questions than answers. Indeed, the molecular approach has revealed novel candidate genes for the various types of human obesity, has suggested that several clinical cases previously defined as monogenic obesity are genetically more complex than previously thought, and has clearly positioned G×E interactions as fundamentally important to understanding the mechanisms involved in fat-mass expansion. As discussed in the present review, despite the fact that our understanding of the genetic, biological, and biochemical factors underlying obesity is currently incomplete, the use of novel molecular approaches is rapidly unraveling this complex metabolic disease.

Monogenic Obesity

To date, nearly 200 cases of human obesity have been associated with a single gene mutation. Furthermore, these mutations all lie in one of 11 genes [6,7]. These cases, which obey Mendelian genetics, are characterized by extremely severe phenotypes that present themselves in childhood and are often associated with additional behavioral, developmental, and endocrine disorders [8]. Initial knowledge concerning monogenic diseases was derived from large-scale linkage analyses in mice that had naturally occurring mutations that led to extreme adiposity. These analyses resulted in the detection of disease loci and the identification of candidate genes [9]. Using such an approach,
the majority of mutations in genes underlying monogenic murine obesity have now been cloned [10].

Indeed, the targeted genetic characterization of naturally occurring obese models, such as the ob/ob, db/db, fat, and tubby mice, led to the discovery of recessive mutations in the genes encoding leptin (Lep or ob), leptin receptor (Lepr or db), carboxypeptidase E (Cpe or fat), and tubby (Tub) [11]. The transfer of this knowledge to clinical cases in which the gene underlying the phenotype was successfully hypothesized validates the roles of some of the aforementioned genes in human monogenic obesity, and clearly positions the leptin/melanocortin pathway as critical in the regulation of whole-body energy homeostasis (Figure 1) [12]. In brief, this hypothalamic pathway is activated following the systemic release of the adipokine LEP and its subsequent interaction with the receptor LEP located on the surface of neurons of the arcuate nucleus of the hypothalamus. The downstream signals that regulate satiety and energy homeostasis are then propagated via proopiomelanocortin (POMC), cocaine- and amphetamine-related transcript (CART), and the melanocortin system [13,14]. While POMC/CART neurons synthesize the anorectic peptide alpha melanocyte stimulating hormone (α-MSH), a separate group of neurons express the orexigenic neuropeptide Y (NPY) and the agouti-related protein (AGRP), which acts as a potent inhibitor of melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R).

Since naturally occurring mutations and the targeted disruption of genes in mouse models (Lep, Lepr, Pomc, Mc4r, and Mc3r) were all found to have key roles in the same molecular pathway, genes in and associated with the leptin/melanocortin pathway became logical candidates to consider in clinical cases where obesity remained unexplained. Stemming from this hypothesis, several additional genes were found to cause monogenic obesity (Figure 1). First, single-minded homolog 1 (Drosophila) (SIM1) was identified in a girl with early-onset obesity and a de novo chromosomal translocation [15]. SIM1 is expressed in the paraventricular nucleus of the hypothalamus, has a role in the melanocortin signaling pathway, and appears to regulate feeding rather

Figure 1. The Leptin/Melanocortin Pathway
The integration of signals from peripheral tissues in the hypothalamus is fundamental to the regulation of energy homeostasis. Distinct neuronal populations propagate the signaling of various molecules to control food intake and satiety. POMC neurons in the arcuate nucleus are activated by leptin and insulin and produce α-MSH, which then activates the MC4R receptor in the paraventricular nucleus, resulting in a satiety signal. The downstream roles of SIM1, BDNF, and TRKB are currently being explored. In contrast, a separate group of neurons expressing NPY and AGRP produce molecules that act as potent inhibitors of MC4R signaling. A dysfunction in these pathways will disrupt energy homeostasis. AGRP, agouti-related protein; α-MSH, alpha melanocyte stimulating hormone receptor; BDNF, brain-derived neurotropic factor; GHR, ghrelin receptor; ISR, insulin receptor; Lepr, leptin receptor; NPY, neuropeptide Y; PC1 and 2, proconvertase 1 and 2; POMC, proopiomelanocortin; SIM1, single-minded homolog 1 (Drosophila); TRKB, tyrosine kinase receptor.

doi:10.1371/journal.pgen.0020188.g001
than energy expenditure [16]. Second, decreased expression of brain-derived neurotrophic factor (BDNF) was recently found to regulate eating behavior [17]. BDNF and its associated neurotrophic tyrosine kinase receptor (TRKB/NTRK2) are both expressed in the ventromedial hypothalamus and are proposed to have a role downstream of MC4R signaling [18]. A mutation in TRKB was identified in an 8-y-old male with a complex development syndrome and severe obesity, and further functional in vitro studies have suggested that mutations impair hypothalamic signaling processes [19,20].

A frequent autosomal-dominant form of obesity stemming from mutations in MC4R was simultaneously reported by two groups, first in family studies and then in case-control studies [21–24]. Since these initial reports, MC4R-linked obesity remains the most prevalent form of monogenic obesity identified to date, representing approximately 2%–3% of childhood and adult obesity [7,25–27]. Mutations have also been reported in the general population, but to a significantly lesser degree [25]. Furthermore, instances have been reported in which individuals in the general population have these mutations but are not obese, suggesting a variable phenotype [25]. Investigating the molecular mechanisms by which loss-of-function mutations in MC4R cause obesity has led to a panel of functional anomalies: abnormal MC4R membrane expression, a defect in the agonist response, and a disruption in the intracellular transport of this protein [28]. In contrast with rare monogenic obesity, even careful clinical analysis does not easily detect obesity stemming from MC4R mutations because of the lack of additional obvious phenotypes. Thus, the question remains whether there are other forms of obesity with a marked genetic influence, such as that noted for MC4R mutation–linked obesity. The recent discovery of rare functional mutations in regions of POMC encoding for a-MSH and leading to childhood obesity with no other observed anomalies (in contrast to the POMC mutations previously described [29]) provides support for the use of genetic screens to identify factors upstream and downstream of MC4R in early-onset and severe human obesity [30].

As the principle goal is to ameliorate the corpulence and metabolic status of obese individuals, cases of monogenic obesity in which gene function is well-characterized can benefit from therapeutic intervention. Leptin therapy in children deficient in this adipokine dramatically reduced body weight, and was accompanied, in some instances, by improved insulinemia and pubertal development [31]. While treatments are not yet available for cases of POMC, PC1-, SIM1-, TRKB-, and MC4R-linked obesity, preliminary studies hint that targeted therapies might not be far away.

Recent studies using neuron-specific LEPR transgenes, a POMC gene-delivery system, and a melanocortin-receptor agonist (MT-II) have all proved efficient in reducing food intake, body weight, and insulin resistance [32–35]. Current MC4R therapeutic peptides are of interest, but have been found to be anorexigenic and to stimulate erectile activity [36–38]; therefore, the development of therapies targeting monogenic obesity will need to circumvent such undesirable side effects. Nevertheless, these studies suggest promising futures for individuals with mutations in genes of the leptin/melanocortin pathway but, as discussed in the remainder of the manuscript, reinforce the enormous challenge lying ahead if therapies are to be developed for individuals with syndromic or polygenic obesity.

### Syndromic Obesity

There are between 20 and 30 Mendelian disorders in which patients are clinically obese, yet are additionally distinguished by mental retardation, dysmorphic features, and organ-specific developmental abnormalities [7,8]. Such cases are referred to as syndromic obesity. These syndromes arise from discrete genetic defects or chromosomal abnormalities, and can be either autosomal or X-linked disorders. However, inasmuch as these cases are well-defined in a clinical context, analyzing the genetic component of these conditions suggests that multiple genes within a biological pathway may produce identical phenotypes [39]. The most common disorders known are Prader-Willi syndrome (PWS), Bardet-Biedl syndrome (BBS), and Alström syndrome, but many others have been reported elsewhere [39].

The most frequent of these syndromes (1 in 25,000 births) is PWS, which is characterized by obesity, hyperphagia, diminished fetal activity, mental retardation, and hypogonadism. This disorder is caused by an absence in the paternal segment 15q11.2–1q12 through chromosomal loss. Several candidate genes in the 15q11–13 region of PWS patients have been studied; however, the molecular basis of hyperphagia remains undefined in part because of the fact that none of the currently available PWS mouse models have an obese phenotype [40]. One candidate protein that may mediate the severe hyperphagia of PWS is the gastric hormone ghrelin [41], via its regulation of hunger and stimulation of growth hormone [8]. Ghrelin’s role is further implied by the positive findings that growth hormone supplementation is capable of reversing several dysfunctional processes associated with PWS [42,43]; however, in the absence of a suitable experimental model, identifying the genetic components of this syndrome will be challenging.

BBS is characterized by early-onset obesity and rod-cone dystrophy, morphological finger abnormalities, learning difficulties, and renal disease, among other clinical traits. Although originally classified in the clinic as a homogeneous syndrome, BBS has since been associated with at least 11 different chromosomal locations, with several mutations identified within some of the following locations: BBS1 on 11q13, BBS2 on 16q21, BBS3 on 3p13, BBS4 on 15q22.3, BBS5 on 2q31, BBS6 on 20p12, BBS7 on 4q27, BBS8 on 14q32.11, BBS9 on 7p14, BBS10 on 12q21.2, and BBS11 on 9q33.1 [44–47]. While BBS was considered to be autosomal-recessive, it has recently been found that the clinical symptoms of certain forms of BBS are related to recessive mutations at one of the BBS loci associated with a heterozygous mutation at a second locus, prompting, for the first time, the hypothesis of a triallelic mode of transmission [46]. Six genes are characterized in BBS, although their functions remain enigmatic to various degrees. For the BBS6 locus, positional cloning identified the MKKS gene, which codes for a chaperone protein. Mutations identified in MKKS result in a shortened chaperone protein and are present in 5%–7% of BBS cases; however, the links between MKKS, its eventual target proteins, and the BBS clinical traits are largely unknown. A newly identified locus, BBS10, has recently been
found to code for C12orf58, a vertebrate-specific chaperone-like protein, and was found to be mutated in 20% of the populations examined from various ethnic backgrounds [45]. Unlike BBS6 and BBS10, the genes associated with BBS1, BBS2, and BBS4 are very different from MKKS and C12orf58 genes, but it is conceivable that they code for protein substrates of these chaperones [49]. Recently, the gene encoding the E3 ubiquitin ligase TRIM32 was identified as the 11th locus associated with BBS, suggesting that the list of genetic components for this syndrome may yet remain incomplete [47]. Fascinating functional studies performed in single-cell organisms have shown that certain BBS genes are specific to ciliated cells [50]. Ciliated cells have a role in mammalian development, contributing to right/left asymmetry, thus enabling the organs (e.g., heart, liver, and lungs) to be correctly positioned within the biological system. Dysfunction in processes affecting ciliated cells may contribute to the alterations in pigmented epithelia and structural anomalies noted in certain organs in patients with BBS; however, the relationship between cilia and obesity remains enigmatic [51]. Preliminary findings suggest that cilia formation is not dependent on BBS gene functionality [52]; rather, the BBS genes may play an important role in intracellular signaling [51]. A recent article by Mak and colleagues used Caenorhabditis elegans to demonstrate the regulation of fat storage by orthologs of both neuronal TUB and BBS1 genes, suggesting the existence of a currently unidentified intertissue signaling pathway that may link ciliated neurons and adipose cells [53]. As such, new fields of research have been opened by the molecular investigation of BBS, most notably regarding the role of ciliated cells in controlling some mechanisms of body-weight regulation.

While syndromic obesity was previously presumed to be under the control of a single gene (and thus was considered monogenic obesity), progress in the post-genomic era has clearly distinguished this type of obesity; however, defining the contribution of multiple genetic factors in a syndrome is significantly more challenging than localizing the single gene involved in monogenic diseases. The difficulty of this task is further amplified if several tissues coordinate regulate phenotype (as possibly exemplified by ghrelin signaling in PWS), indicating that the integrative field of systems biology may hold the key to identifying both the within- and the between-tissue regulators underlying syndromes.

**Polygenic Obesity**

Polygenic, or common, obesity arises when an individual’s genetic makeup is susceptible to an environment that promotes energy consumption over energy expenditure. Most Westernized societies have an environment that favors weight gain rather than loss because of food abundance and lack of physical activity, thus positioning common obesity as a major epidemic currently challenging these societies. Many excellent reviews have been published in which the genetic complexity and the challenges in dissecting the perturbed biology underlying common obesity have been outlined [7,14,54–56]. Perhaps the greatest obstacle hindering progress is the issue of replication. While independent replication of a novel association is mandatory, it is important to stress that our current degree of understanding of G×E interactions should prevent an unreplicated result from immediately being discarded. Complex traits are highly dependent on G×E interactions; however, inasmuch as this is widely accepted, a question persists: how can one account for and control all possible influences within an experimental design that may affect data interpretation and ultimately experimental conclusions? Although accomplishing this goal is feasible with genetically identical mice, in humans it is nearly impossible. The individual complexity in humans relates to the alleles that influence common diseases in different genetic backgrounds, and to variable genetic combinations eventually influenced by different epigenetic (including in utero) or environmental factors during an individual’s lifetime (the role of epigenetics in obesity and its downstream consequences is a field unto itself, and has been thoroughly reviewed in [57,58]) (Figure 2). The precise degree to which genes eventually contribute to complex traits remains poorly defined, and the importance of subtle environmental factors may simply not be appreciated. Thus, as illustrated below by two independent examples, both replicated and unreplicated findings should be considered to be of interest at this early stage in unraveling the genetics of obesity.

Studies of polygenic obesity are based on the analysis of single nucleotide polymorphisms (SNPs) or repetition of bases (polyCAs or microsatellites) located within or near a candidate gene, where a candidate gene is one that meets a number of criteria, such as its proximity to a quantitative trait locus or its having a phenotypic effect following genetic manipulation (e.g., knock-out and knock-in models) [59]. Should a candidate-gene variant appear promising based on results derived from in vitro and animal-model studies, its association with the obese phenotype is then examined in case-control and family studies [60]; however, unlike monogenic obesity, many genes and chromosomal regions contribute to defining the common obese phenotype (Figure 3) [6,61]. These genes have been implicated in a wide variety of biological functions, such as the regulation of food intake, energy expenditure, lipid and glucose metabolism, and adipose tissue development; however, despite having this ever-increasing gene catalog at our disposal, using this knowledge to unravel the molecular mechanisms underlying obesity is challenging. Indeed, not only is the number of genes associated with obesity high, but variants in some of these genes are demonstrating the importance of polymorphisms in the “interpretation” of environmental stimuli [3]. In contrast to genetically identical mice whose environments can be rigorously controlled, the genetic and environmental diversity in humans has proved problematic for data replication (i.e., to date, only 22 of 244 candidate genes for obesity are supported by at least five positive studies) [6,60,62]. The result can be conflicting findings that cast doubt on potentially interesting candidate genes. For example, an association between three SNPs of GAD2, which codes for the 65-kDa subunit of the glutamic acid decarboxylase enzyme, and morbid obesity was identified in a French population following a genome-wide scan [63]; however, independent replication in a larger German population could not be achieved [64]. Although this example raises questions concerning the role of GAD2 in obesity, it would be premature to discount GAD2’s involvement entirely [65]. This notion may also apply to additional candidates (e.g., ectonucleotide pyrophosphatase/phosphodiesterase 1 [ENPP1] and solute carrier family 6, member 14 [SLC6A14])
emerging from genome-wide scans, as they may also face replication issues.

In many cases, a failure to replicate data is related to the cohort size in which the association was first detected. Indeed, because the contribution of any given gene to the phenotype of a complex trait is often minimal, a large cohort size is required if statistical significance is to be achieved; however, the caveat is that the more associations examined, the greater the risk of type-I errors (i.e., false-positive rate). Statistical approaches such as linkage disequilibrium threshold values and permutation analyses have proven useful [66], but an ingenious approach recently described by Herbert and colleagues will undoubtedly provide a template for future association studies [67]. Using a multi-stage design, in which the number of SNPs considered is reduced at each step without sacrificing genome-wide significance, the authors selected the top ten SNPs for further analysis, and only one, a SNP variant near the \textit{INSIG2} gene, was associated with obesity. While more common statistical tests, such as the Bonferroni and Hochberg corrections, did not identify this variant, the multi-stage approach employed by the authors proved accurate, as this variant was replicated in four out of five independent populations (no significant association was found using the Nurses Health Study cohort) [60,67]. Thus, the use of novel and creative approaches may provide the means to circumvent classical statistical obstacles in identifying new candidate genes and possible G\times E interactions.

**Future Challenges**

Our ability to identify promising candidates has progressed rapidly since entering the post-genomic era. Not only is this era characterized by immense progress in molecular biology tools (e.g., microarrays, mass spectrometry, and bioinformatics), it has also prompted the creation of international consortiums that work together towards a common goal [68,69]. Whether consortiums aim to sequence genomes, develop classification terminologies, create publicly accessible databases (such as HapMap), or provide scientific and ethical guidelines for emerging fields, the result is the same: pooling together resources and knowledge from laboratories around the world realizes ambitious goals far more quickly and accurately than an individual research group working alone. For example, well-controlled dietary-intervention studies are currently underway in large populations in Europe, such as in the NUGENOB (http://www.nugenob.com) and Diogenes (http://www.diogenes-eu.org) programs. Such programs, comprising both academic and industrial partners, aim to study G\times E interactions and identify those genetic determinants susceptible to environmental stimuli that are capable of influencing obesity development [69,70].

Within such programs, the use of comprehensive platforms (i.e., genetics, transcriptomics, peptidomics, and metabolomics) coupled with clinical data will play a predominant role in elucidating the perturbed functions leading to obesity. Such a “hypothesis-generating” approach promises to identify candidate genes that will undoubtedly implicate novel biological pathways capable of affecting energy status and will enhance our understanding of the evolutionary stages in cellular adaptation during the development of obesity; however, it is important to stress that the association of a gene with a complex trait indicates only a possible risk rather than the causative gene. As such, the research community must err on the side of caution when positioning genes/SNPs in relation to disease. No single SNP
will cause obesity; however, a combination of variants exposed to so-called obesogenic environmental stimuli will increase the relative risk that an individual will develop the disease. Alternatively, SNPs may also have a beneficial role by offering a degree of protection against obesity. Recent evidence has demonstrated that the infrequent V103I polymorphism in MC4R is negatively associated with serum triglyceride levels, body mass index, and obesity [71,72]. As such, genetic variations in MC4R can lead to both loss and gain of function [73]. Such a finding highlights the importance of searching for SNPs overrepresented in both obese and lean populations. Thus, when looking at the future promise of personalized medicine and nutrition, one must consider both sides of the coin. One side is purely beneficial, where the health and well-being of an individual is improved using information in their genetic blueprint. The other side concerns the ethics of possessing such knowledge, where the details of an individual’s genetic makeup may be used inappropriately (e.g., discrimination in society). While new technologies and international consortiums will enable the research community to unravel the genetics of complex traits and realize the ambitious goal of personalization more quickly, the future ethical handling of this information will prove to be a far greater challenge, with the potential for drastic implications.

Conclusions

In the context of gene–gene and G×E interactions, providing a list of fail-proof guidelines that guarantee the identification of novel candidate genes important in defining complex traits is challenging, as issues such as replication, multiple testing, and sample size will continue to be handled on an experiment-by-experiment basis. Progress in the knowledge of the human genome, the development of comprehensive technologies, and new analytical strategies will permit both the genetic and environmental aspects of complex traits to be addressed simultaneously; however, success will ultimately lie with international consortiums that
pool together expertise and resources to define and functionally annotate the genetic factors underlying the various forms of obesity.

Supporting Information

Acknowledgments

The authors would like to thank Drs. B. Dubern and A. Basdevant for reviewing the manuscript, and Dr. Dubern for providing the template for Figure 1.

Author contributions. DMM and KC wrote the paper.

Funding. The authors did not receive specific funding for this article.

Competing interests. The authors have declared that no competing interests exist.

References

1. Lunnhof JE, Pirmohamed M, Gurwitz D (2006) Personalized medicine: Decades away? Pharmacogenomics 7: 237–241.
2. Hunter DJ (2005) Gene-environment interactions in human diseases. Nat Rev Genet 6: 287–298.
3. Mutch DM, Wahli W, Williamson G (2005) Nutrigenomics and nutrigenetics: The emerging faces of nutrition. FASEB J 19: 252–262.
4. Kaput J, Ordovas JM, Ferguson L, van Ommen B, Rodriguez RL, et al. (2005) Absence of a large effect of common candidate genes on body adiposity. Endocrinology 146: 3732–3738.
5. Ardlie KG, Kruglyak L, Seielstad M (2002) Patterns of linkage disequilibrium in the human genome. Nat Genet 31: 44–51.
6. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, et al. (2004) The human obesity gene map. Nat Genet 36: 497–508.
7. Bell CG, Walley AJ, Froguel P (2005) The genetics of human obesity. Nat Rev Genet 6: 287–298.
8. Farooqi IS, O'Rahilly S (2005) Monogenic obesity in humans. Annu Rev Med 56: 435–458.
9. Sebhat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, et al. (2002) Design and development of a new pharmacogenomics resource. Nat Genet 31: 44–51.
10. Katsanis N, Lupski JR, Beales PL (2001) Exploring the molecular basis of neural tube defects. Nat Genet 28: 113–114.
11. Ellacott KL, Cone RD (2006) The role of the central melanocortin system in body adiposity. Endocrinology 146: 3732–3738.
12. Coll AP, Farooqi IS, Challis BG, Yeo GS, O'Rahilly S (2004) MC4R haploinsufficiency impairs melanocortin-mediated anorexia and activation of paraventricular nucleus neurons. Mol Endocrinol 28: 2485–2492.
13. Kernie SG, Liebl DJ, Parada LF (2000) BDNF regulates eating behavior and locomotor activity in mice. EMBO J 19: 1290–1300.
14. Xu B, Goulding EH, Zang K, Cepko D, Cone RD, et al. (2003) Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 6: 756–742.
15. Gray J, Yeo G, Hung C, Keogh J, Clayton P, et al. (2006) Functional characterization of human NTRK2 mutations identified in patients with severe early-onset obesity. Int J Obes (Lond) 30: 810–812.
16. Vaisse C, Clement K, Guy-Grand B, Frouquet P (1998) A frame shift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 20: 113–114.
17. Yeo GS, Farooqi IS, Amimian S, Halsall DJ, Stanhope RG, et al. (1998) A frame shift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20: 111–112.
18. Vaisse C, Clement K, Durand F, Herchberg S, Guy-Grand B, et al. (2000) Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106: 253–262.
19. Farooqi IS, Yeo GS, Keogh J, Amimian S, Jebb SA, et al. (2000) Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 106: 271–279.
20. Hinney A, Bettecken T, Tarnow P, Brunn H, Reichwald K, et al. (2006) Prevalence, spectrum, and functional characterization of melanocortin-4 receptor gene mutations in a representative population-based sample and obese adults from Germany. J Clin Endocrinol Metab 91: 1761–1769.
21. Lebrato-Berthelier C, Dubern B, Lacorte JM, Picard F, Shapiro A, et al. (2006) Characterization of a new Bardet-Biedl syndrome gene. Am J Hum Genet 80: 113–114.
22. Lebrato-Berthelier C, Cavazo M, Dubern B, Shapiro A, Stunf CL, et al. (2003) Molecular genetics of human obesity-associated MC4R mutations. Ann N Y Acad Sci 994: 49–57.
23. How G, MacKenzie RG (1999) Functional characterization of mutations in melanocortin-4 receptor associated with human obesity. J Biol Chem 274: 53816–53822.
24. Krude H, Biehermann H, Luck W, Horn R, Brabant G, et al. (1997) Early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19: 155–157.
25. Lee YS, Challis BG, Thompson DA, Yeo GS, Keogh J, et al. (2006) A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human cell energy. Cell Metab 3: 135–140.
26. Farooqi IS, Matarase G, Lord GM, Keogh J, Lawrence E, et al. (2002) Beneficial effects of leptin on obesity. T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110: 1095–1103.
27. Gettinger SJ (2005) Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 111: 1–15.
28. de Luca C, Kowalski TJ, Zhang Y, Elmqrist JK, Lee C, et al. (2005) Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes. J Clin Invest 115: 3484–3493.
29. Li G, Zhang Y, Wilsey JT, Stuewe PJ (2005) Hypothalamic pro-opiomelanocortin gene delivery ameliorates obesity and glucose intolerance in aged rats. Diabetologia 48: 2376–2385.
30. Seeley RJ, Bукlow ML, Wilmar KA, Matthews CC, Reizes O, et al. (2005) The effect of the melanocortin agonist, MT-II, on the defended level of body adiposity. Endocrinology 146: 3732–3738.
31. Mollinoff PB, Shadian AM, Earle D, Diamond LE, Quon CY (2003) PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 994: 96–102.
32. Sebat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, et al. (2002) Design and pharmacology of N-[3R]-1,2,3,4-tetrahydroisquinolin-3-ylcarbonyl-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem 45: 4506–4503.
33. Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, et al. (2003) MT-II induces penile erection via brain and spinal mechanisms. Ann N Y Acad Sci 994: 90–95.
34. Chung WR, Leibl RL (2005) Molecular physiology of syndromic obesity in humans. Trends Endocrinol Metab 16: 267–272.
35. Goldstone AP (2004) Prader-Willi syndrome: Advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 15: 12–20.
36. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, et al. (2002) Elevated plasma ghrelin levels in Prader-Willi syndrome. J Pediatr 148: 180–183.
37. Katsanis N, Lupski JR, Beales PL (2001) Exploring the molecular basis of neural tube defects. Nat Genet 28: 113–114.
38. Katsanis N, Lupski JR, Beales PL (2001) Exploring the molecular basis of neural tube defects. Nat Genet 28: 113–114.
39. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, et al. (2004) Growth hormone therapy in children with Prader-Willi syndrome. J Pediatr 144: 416–419.
40. Sebat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, et al. (2002) Design and pharmacology of N-[3R]-1,2,3,4-tetrahydroisquinolin-3-ylcarbonyl-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J Med Chem 45: 4506–4503.
41. Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, et al. (2003) MT-II induces penile erection via brain and spinal mechanisms. Ann N Y Acad Sci 994: 90–95.
42. Chung WR, Leibl RL (2005) Molecular physiology of syndromic obesity in humans. Trends Endocrinol Metab 16: 267–272.
48. Eichers ER, Lewis RA, Katsanis N, Lupski JR (2004) Triallelic inheritance: A bridge between Mendelian and multifactorial traits. Ann Med 36: 262–272.

49. Slavotinek AM, Searby C, Al-Gazali L, Hennekam RC, Schrander-Stumpel C, et al. (2002) Mutation analysis of the MKKS gene in McKusick-Kaufman syndrome and selected Bardet-Biedl syndrome patients. Hum Genet 110: 561–567.

50. Fan Y, Esmail MA, Ansley SJ, Blacque OE, Boroevich K, et al. (2004) Mutations in a member of the Ras superfamily of small GTP-binding proteins causes Bardet-Biedl syndrome. Nat Genet 36: 989–993.

51. Marshall WF, Nonaka S (2006) Cilia: Tuning in to the cell's antenna. Curr Biol 16: R604–R614.

52. Mykytyn K, Mullins RF, Andrews M, Chiang AP, Swiderski RE, et al. (2004) Bardet-Biedl syndrome type 4 (BBS4)-null mice implicate Bbs4 in flagella formation but not global cilia assembly. Proc Natl Acad Sci U S A 101: 8664–8669.

53. Mak HY, Nelson LS, Basson M, Johnson CD, Ruvkun G (2006) Polygenic control of C. elegans fat storage. Nat Genet 38: 363–368.

54. Roche HM, Phillips C, Gibney MJ (2005) The metabolic syndrome: The crossroads of diet and genetics. Proc Nutr Soc 64: 371–377.

55. Saris WH, Harper A (2005) DiOGenes: A multidisciplinary offensive focused on the obesity epidemic. Obes Rev 6: 175–176.

64. Swarbrick MM, Waldenmaier B, Pennacchio LA, Lind DL, Cavazos MM, et al. (2005) Lack of support for the association between GAD2 polymorphisms and severe human obesity. PLoS Biol 3: doi:10.1371/journal.pbio.0030315.

65. Tiwari HK, Bouchard L, Perusse L, Allison DB (2005) Is GAD2 on chromosome 10p12 a potential candidate gene for morbid obesity? Nutr Rev 63: 315–319.

66. Ahiola O, Angel JM, Avner P, Bachmanov AA, Belknap JK, et al. (2003) The nature and identification of quantitative trait loci: A community's view. Nat Rev Genet 4: 911–916.

67. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, et al. (2006) A common genetic variant is associated with adult and childhood obesity. Science 312: 279–283.